SARS-CoV-2 coinfections among pertussis cases identified through the Enhanced Pertussis Surveillance system in the United States, January 2020–February 2023

Bacterial and viral respiratory coinfections are common, but the prevalence of SARS-CoV-2 infections among pertussis cases has not been estimated. We examine the prevalence and temporality of SARS-CoV-2 infections among pertussis patients and describe pertussis clinical severity among patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PloS one Ročník 19; číslo 12; s. e0311488
Hlavní autoři: Berry, Isha, Cole, Matthew, Silk, Benjamin, Havers, Fiona P., Youngkin, Erin, Misiorski, Adam, Sefton, Samantha, Vang, Yeng, Stanislawski, Emma, McGuire, Suzanne, Silhan, Noel, Skoff, Tami H, Rubis, Amy B.
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Public Library of Science 04.12.2024
Public Library of Science (PLoS)
Témata:
Adolescent
Adult
African Americans
Aged
Biology and life sciences
Case reports
Child
Child, Preschool
Coinfection - epidemiology
Comorbidity
Cough
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
COVID-19 vaccines
Demographics
Diagnosis
Disease control
Encephalopathy
Female
Hispanic Americans
Hospitalization
Humans
Illnesses
Immunization
Infant
Infections
Male
Medical laboratories
Medicine and Health Sciences
Middle Aged
Pandemics
Pathogens
Pertussis
Pneumonia
Prevalence
Risk factors
SARS-CoV-2 - isolation & purification
Seizures
Severe acute respiratory syndrome coronavirus 2
Surveillance
Surveillance systems
United States - epidemiology
Viral diseases
Viral infections
Whooping cough
Whooping Cough - complications
Whooping Cough - epidemiology
Young Adult
United States
United States > US
ISSN:1932-6203, 1932-6203
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Bacterial and viral respiratory coinfections are common, but the prevalence of SARS-CoV-2 infections among pertussis cases has not been estimated. We examine the prevalence and temporality of SARS-CoV-2 infections among pertussis patients and describe pertussis clinical severity among patients with and without SARS-CoV-2 coinfections. Confirmed and probable pertussis cases among individuals with cough onset between January 1, 2020 and February 15, 2023 were identified through surveillance in seven Enhanced Pertussis Surveillance (EPS) sites. Pertussis cases with a laboratory-confirmed SARS-CoV-2 infection detected within 30 days before or after pertussis cough onset were defined as coinfections. We describe patient demographics, symptoms, and severe complications and outcomes (seizures, encephalopathy, pneumonia, hospitalization, or death) by coinfection status. Among 765 pertussis cases reported during the study period, the prevalence of SARS-CoV-2 coinfections was 0.78% [6/765]. Among the six patients meeting the coinfection definition, the majority (83.3% [5/6]) had SARS-CoV-2 infections detected following pertussis cough onset. Compared to those with no known coinfection, a higher proportion of those with coinfections reported severe complications or outcomes (50.0% [3/6] vs. 5.2% [36/694]). Although the prevalence of pertussis patients with SARS-CoV-2 coinfections was low, patients with coinfections reported more severe complications and outcomes compared to those with pertussis alone. Given the decline in reported pertussis cases during the COVID-19 pandemic, continued monitoring of pertussis incidence alongside respiratory viral infections will be important as the pertussis burden returns to pre-pandemic levels.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0311488